KRAS and cancer: Whilst our data mean that we do not now think that rare codons explain why KRAS is more often mutated in cancer, the rare codon experiments and work by others have conclusively demonstrated that Ras dosage has a significant influence on Ras oncogenic potential [9–12, 16].